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Vascular Procedure Outcome Payer Status
Adjusted* Odds
Ratio (95% CI) P Value
Bypass Surgery Death Medicare 1.40 (1.25-1.58) <0.001
Medicaid 0.82 (0.66-1.03) 0.94
Self-Pay 0.96 (0.68-1.35) 0.80
Endovascular
Treatment
Death Medicare 1.40 (1.26-1.55) <0.001
Medicaid 1.35 (1.13-1.62) 0.001
Self-Pay 1.31 (0.97-1.78) 0.08
Amputation Death Medicare 1.56 (1.39-1.74) <0.001
Medicaid 1.41 (1.20-1.66) <0.001
Self-Pay 1.11 (0.80-1.53) 0.54
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: 100% of CTO’s in this series were crossed successfully via the true lumen
without the use of assist or re-entry devices. Mean CTO crossing ﬂuoroscopy time was
0.24 (14.4 seconds)  0.36 minutes using the Ocelot. Mean lesion length treated was
18.6 cm (18.63  8.58 cm) (Table 1). The treated lesions represented a spectrum of
calciﬁcation (mild/none¼2; moderate¼8; severe¼6).
Conclusions: The Ocelot catheter successfully crosses peripheral arterial chronic total
occlusions while eliminating, or signiﬁcantly reducing ﬂuoroscopic exposure and
associated contrast administration.
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Background: Chronic total occlusions (CTO) of the superﬁcial femoral artery (SFA)
are a challenging subset of lesions encountered in peripheral interventions. CTO’s of
the SFA are commonly crossed either with an intraluminal (IL) or re-entry device
assisted subintimal (SI) approach followed by stenting. Even though both these
techniques have a high immediate procedural success rate the long term outcomes of
each approach are not well studied.
Methods: We studied 215 patients (pts) (254 limbs) with obstructive SFA disease
treated with nitinol self-expanding stents of comparable lesion length; there were 205
(81%) limbs with CTO and 49 (19%) pts with non-CTO. We analyzed in-stent
restenosis (ISR) rates as well as demographic, procedural and laboratory character-







Age (years) 73.029.1 71.94 9.5 74.9 7.9
Mean stented length, mm 248.872.5 251.8199.2 280.091.9
GFR ml/min 52.322.3 62.6  20.5 58.621.9
Rutherford class 3 34(70%) 119(79%) 35(70%)
Rutheford class ‡4 15(30%) 32(21%) 15(30%)
Mean run-off score 5.12.5 3.92.8 3.92.9
Mean follow up period, mo 18.414.7 20.516.5 17.216.9
Mean duration to ISR, mo 13.311.8 13.09.2 13.310.4
ISR rate (%) 23(47%) 66(42%) 24(48%)Results: Baseline and procedural characteristcis of the studied groups presented in the
table. There were no signiﬁcant differences in the mean time to ISR, stented lesion
length, as well as other demographic, laboratory, and procedural parameters between
the studied groups except mean run-off score that was higher in non-CTO group (non
CTO vs. SI CTO, p¼0.05; non-CTO vs. IL CTO, p¼0.01). During follow up period of
19.2616.14 months, ISR was diagnosed in: 23 (47%) of pts of non-CTO group; 66
(42%) of IL CTO; and 24 (48%)pts of SI CTO group respectively. There were no
signiﬁcant differences in ISR rates between the groups (non-CTO vs. IL CTO,
p¼0.59; non-CTO vs. SI CTO, p¼0.9; IL CTO vs. SI CTO, p¼0.5).B158 JACC Vol 64/1Conclusions: In patients with long SFA lesions, we observed similar SFA ISR rates
between patients with and without CTO. Furthermore, in CTO group the long term
vessel patency was not affected by whether CTO was crossed using intraluminal or
subintimal approach.
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Background: Peripheral arterial disease (PAD) affects >8 million in US. Previous
studies suggested that patients with Medicare, Medicaid or no insurance received
poorer quality of care leading to worse outcomes in comparison to patients with
private insurance.
Methods: We analyzed all hospitalized PAD patients records from 01/2007 through
12/2011 in Nationwide Inpatient Sample (NIS) database. Temporal trends of pre-
senting diagnoses as well as vascular procedures performed (endovascular treatment,
bypass surgery and amputation) were analyzed. In addition, the unadjusted and
adjusted rates of adverse in-hospital outcomes (death, myocardial infarction, bleeding,
vascular complications, and acute renal failure (ARF)) were examined.
Results: The frequency of endovascular treatment for claudication from 2007 to 2011
decreased by 39.4%, while the annual incidence of bypass surgery and amputation
remained unchanged. Medicare (n¼731,264) and Medicaid (n¼72,050) patients were
more likely to undergo amputation than private insurance/HMO population
(n¼22,896), (adjusted OR 1.13, 95%CI 1.10-1.16, p< 0.001 and OR 1.24, 95%CI
1.20-1.29, p< 0.001, respectively). Both Medicare and Medicaid patients were less
likely to undergo bypass surgery (adjusted OR 0.82, 95%CI 0.81-0.84, p< 0.001 for
Medicare and OR 0.87, 95%CI 0.85-0.90, p< 0.001 for Medicaid), but more likely to
undergo endovascular procedures (adjusted OR 1.18, 95%CI 1.17-1.20, p< 0.001 for
Medicare and OR 1.03, 95%CI 1.01-1.06, p¼0.02 for Medicaid). Medicare and
Medicaid status was associated with worse in-hospital outcomes (Table).Conclusions: Medicare and Medicaid patients were more likely to undergo amputa-
tion and less likely to undergo vascular bypass surgery. Medicare or Medicaid status
was associated with worse in-hospital outcomes compared to private insurance/HMO
status.
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Background: Recent studies have reported presence of poor run-off vessels was
related to lower patency rates of SFA lesions, however it is still uncertain the role of
below-the-knee intervention (BTKI) for patency of SFA. The aim of this study was to
evaluate the impact of BTKI on the patency of SFA lesions after concomitant
treatment.
Methods: Percutaneous angioplasty with primary stenting at SFA was performed in
110 limbs (65 with BTKI) with 0 or 1 patent run-off vessel. Loss of patency was
deﬁned that aggravated ischemic symptoms with deterioration of calf-brachial index
by 0.15 from the maximum postprocedural level or stenosis by duplex ultrasound,1/Suppl B j September 13–17, 2014 j TCT Abstracts/Iliac and SFA
Variable Laser (N ¼ 37) No Laser (N ¼ 81) P value
Age, years 73  11 69  11 0.06
Male (%) 18 (49) 41 (51) 0.9
ABI 0.70  0.22 0.65  0.18 0.3
TBI 0.33  0.21 0.37  0.18 0.4
Total lesion length, mm 185  118 114  106 0.001
Reference vessel
diameter, mm
5.3  0.6 5.3  0.7 0.9
TASC II C/D 21 (64) 25 (35) 0.007
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMangiography or computed tomography. We compared the outcomes of SFA angio-
plasty with versus without combined BTKI.
Results: More limbs treated with BTKI showed absence of any run-off vessel before
angioplasty (56% vs 19%, p< 0.001). Other baseline characteristics were similar. SFA
lesion length did not differ between the limbs with and without BTKI (226101 vs
24872 mm, p¼0.214). At 1-year follow-up, overall mortality rate was 14% and 7%
for patients with and without BTKI, retrospectively (p¼0.235). There was no major
amputation in both groups. Unexpected minor amputation rate was 11% and 3%,
respectively (p¼0.120). Target vessel revascularization rate for limbs with BTKI was
18% versus 11% for limbs without BTKI (p¼0.292). Kaplan-Meier analysis showed
limbs with BTKI have a lower 1 year patency rate (log rank p¼0.032) than those
without BTKI.Tosaka Class 0.001
1 5 (14) 32 (40)
2 12 (32) 32 (40)
3 20 (54) 17 (20)Conclusions: BTKI showed no beneﬁcial impact on outcomes of SFA lesions after
angioplasty in limbs with poor run-off vessels.
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Background: Femoropoliteal in-stent restenosis (FP-ISR) is associated with high
rates of recurrent stenosis and stent occlusion after endovascular therapy. Laser
atherectomy provides neointimal debulking and possible subsequent improved
patency in the treatment of FP-ISR.
Methods: All cases of FP-ISR treated between 2006-2013 were retrospectively
identiﬁed. FP-ISR was divided into three angiographic classes: Class I ( 50 mm
length); Class II (>50 mm length); and Class III (in-stent occlusion). Baseline de-
mographics and lesion angiographic characteristics were compared between groups.
Recurrent stenosis, as assessed by duplex ultrasound, was determined routinely at 3-4
month intervals up to 24 months post-intervention.
Results: One hundred and eighteen patients underwent endovascular treatment of
FP-ISR. Thirty-seven patients (31%) were treated with laser atherectomy and balloon
angioplasty, while 81 patients were treated with balloon angioplasty. Patients treated
with laser atherectomy had longer mean lesion length of FP-ISR (185 mm vs. 116
mm, p¼0.001) and were more likely to have Class III ISR (54% vs. 20%, p¼0.001)
and TASC C/D lesions (64% vs. 35%, p¼0.007). Procedural success was achieved in
100% of laser-assisted cases and 98% of non-laser-assisted cases. Complication rates
were low, with four distal embolizations in the laser group and one in the non-laser
group (p¼0.01). There was no association between laser atherectomy and rates of
recurrent stenosis or occlusion for patients with Class I or Class II FP-ISR. In com-
parison, patients with Class III FP-ISR treated with laser atherectomy were less likely
to develop recurrent stenosis at one year (54% vs. 91%, p¼0.05) and two year (69%
vs. 100%, p¼0.05) follow-up.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/IliaConclusions: Laser atherectomy with adjunctive balloon angioplasty may be asso-
ciated with improved patency when used to treat complex FP-ISR, including longer
lesions and in-stent occlusions.
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Background: Previous studies revealed that diabetes mellitus is associated with the
early restenosis after nitinol stenting in the femoropopliteal (FP) disease. The purpose
of this study is to investigate the advantage of endovascular therapy (EVT) with drug
eluting stents (DES) for FP lesions in diabetic patients.
Methods: This is a single center, retrospective observational study. Between July
2008 and April 2013, 101 FP lesions in 76 diabetic patients were treated with bare
metal stents (BMS group). 52 FP lesions in 42 diabetic patients were treated with
Zilver PTX paclitaxel-eluting nitinol stents (DES group). We evaluate the clinical
outcomes at 8 months after EVT. Stent patency was assessed by either duplex ul-
trasound or angiography.
Results: Follow-up rate at 8 months were 96% (73 patients) in BMS group and 93%
(39 patients) in DES group. Primary patency rates at 8 months were 92.9% with BMS
and 89.6% with DES . (p¼0.50) Major adverse limb events (MALE) occurred in 3
limbs with BMS and 4 limbs with DES in 8 months after stenting. (p¼0.14) Survival
rate at 8 months were similar. (95.9% vs 89.4% p¼0.21) Event-free survival rate
(freedom from all death, MALE and restenosis) were not signiﬁcant different. (87.7%
vs 76.9% p¼0.15).
Conclusions: FP stenting for diabetic patients with DES offers no signiﬁcant
advantage over BMS in middle- term clinical outcome.
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Background: It has not been reported that intravascular ultrasound (IVUS) ﬁndings
correlate with drug eluting stent (DES) restenosis after endovascular therapy for
femoropopliteal lesions. So we investigated that in this study.
Methods: This was a single center non-randomized retrospective study. From April
2012 to March 2013, a total of 71 consecutive de novo femoropopliteal lesions in
patients who underwent intravascular ultrasound (IVUS) after DES implantation were
included. The mean follow-up period was 124 months. In-stent restenosis (ISR) was
deﬁned as a peak systolic velocity ratio >2.4 on duplex ultrasonography or >75%
stenosis on angiography. ISR were detected in 14 lesions (19.7%). Subjects were
classiﬁed into two groups: the patients with ISR (ISR group, 14 lesions, 12 patients)
and without ISR (non-ISR group, 57 lesions, 49 patients). We compared post-pro-
cedural IVUS ﬁndings between two groups.
Results: For baseline patients and lesion characteristics, the percentage of women was
higher in ISR group than non-ISR group (83.3% vs. 20.4%, p< 0.05). There were no
signiﬁcant differences between two groups in diabetes mellitus (33.3% vs. 32.7%,
p¼0.96), hemodialysis (8.3% vs. 26.5%, p¼0.18), TASC II classiﬁed C or D lesions
(28.6% vs. 35.1%, p¼0.64), and critical limb ischemia (33.3% vs. 53.0%, p¼0.22).c and SFA B159
